Feasibility, Acceptability and Appropriateness of MedViewer: A Novel Hair-Based Antiretroviral Real-Time Clinical Monitoring Tool Providing Adherence Feedback to Patients and Their Providers

AIDS Behav. 2023 Dec;27(12):3886-3904. doi: 10.1007/s10461-023-04104-1. Epub 2023 Jul 26.

Abstract

Antiretroviral therapy (ART) adherence is key to achieving viral load suppression and ending the HIV epidemic but monitoring and supporting adherence using current interventions is challenging. We assessed the feasibility, acceptability and appropriateness of MedViewer (MV), a novel intervention that provides real-time adherence feedback for patients and providers using infra-red matrix-assisted laser desorption electrospray ionization (IR-MALDESI) for mass spectrometry imaging of daily ART concentrations in patients' hair. We used mixed methods to feasibility test MV at a busy Infectious Diseases (ID) clinic, enrolling 16 providers and 36 patients. Providers underwent standardized training; patients and providers watched an 8-min informational video about MV. We collected patient and provider data at baseline and within 24 h of clinic visits and, with patients, approximately 1 month after clinic visits. MedViewer was feasible, liked by patients and providers, and perceived to help facilitate adherence conversations and motivate patients to improve adherence. Trial Registration: NCT04232540.

Keywords: Antiretroviral adherence; Clinical drug monitoring; Interventions; Medication adherence.

MeSH terms

  • Anti-HIV Agents* / analysis
  • Anti-HIV Agents* / therapeutic use
  • Anti-Retroviral Agents / therapeutic use
  • Feasibility Studies
  • Feedback
  • HIV Infections* / drug therapy
  • Hair / chemistry
  • Humans
  • Medication Adherence

Substances

  • Anti-Retroviral Agents
  • Anti-HIV Agents

Associated data

  • ClinicalTrials.gov/NCT04232540